Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $850.4 million.

  • Avidity Biosciences' Cash from Financing Activities rose 14830.81% to $850.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $869.8 million, marking a year-over-year decrease of 2814.68%. This contributed to the annual value of $1.2 billion for FY2024, which is 117030.28% up from last year.
  • Latest data reveals that Avidity Biosciences reported Cash from Financing Activities of $850.4 million as of Q3 2025, which was up 14830.81% from $3.8 million recorded in Q2 2025.
  • Avidity Biosciences' Cash from Financing Activities' 5-year high stood at $850.4 million during Q3 2025, with a 5-year trough of $17000.0 in Q1 2021.
  • In the last 5 years, Avidity Biosciences' Cash from Financing Activities had a median value of $31.9 million in 2023 and averaged $140.3 million.
  • In the last 5 years, Avidity Biosciences' Cash from Financing Activities tumbled by 9989.9% in 2023 and then soared by 85606000.0% in 2024.
  • Quarter analysis of 5 years shows Avidity Biosciences' Cash from Financing Activities stood at $20.7 million in 2021, then soared by 1076.28% to $243.7 million in 2022, then tumbled by 86.91% to $31.9 million in 2023, then plummeted by 56.97% to $13.7 million in 2024, then soared by 6096.2% to $850.4 million in 2025.
  • Its Cash from Financing Activities stands at $850.4 million for Q3 2025, versus $3.8 million for Q2 2025 and $1.9 million for Q1 2025.